-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Scientists at St.
The findings were published in the journal Cell
After treatment, cancer sometimes comes back, and researchers know that a small subset of cancer cells can sometimes develop drug resistance that persists after treatment
Corresponding author Doug Green, PhD, Chair of the Department of Immunology, said: "For cancer cells, nothing that kills them makes them stronger
near-death experience
Many drugs used to treat cancer trigger apoptosis
The team showed in the laboratory that these persistent cells did indeed begin to die, and that this near-death experience was key to their survival
"This persistence phenomenon is caused by a 'near-death experience' that engages the mitochondrial apoptotic pathway without dying," Green said
Simultaneous promotion of survival and inhibition of apoptosis may also explain why persistent cells develop resistance to treatments other than the original drugs used to treat cancer
potential drug targets
The research could provide the basis for drugs that prevent cancer recurrence by interfering with a key protein in the stress response
In persistent cells, the stress response leads to an increase in the intracellular protein activating transcription factor 4 (ATF4)
The team found that genes regulated by ATF4 in their persisting cells were similarly regulated in cancer cells from patients who survived chemotherapy, suggesting that this process occurs during cancer treatment
continuing pattern
The researchers came up with a model for how persisters could be formed